The Effect of Escitalopram Treatment Compared to Placebo on Improving the Quality of Life and Hospitalization Rate of Patients with Systolic Heart Failure and Depression: A Randomized Controlled Trial
International Journal of Cardiovascular Practice · 14.11.2026 · 11 (2)
DOI: 10.5812/intjcardiovascpract-175695 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cardiovascular Practice, online erschienen am 14.11.2026. Verfasst von Roxana Sadeghi und 4 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Herzinsuffizienz, Depression
Abstract (Originalsprache)
Background
Research indicates that individuals with heart failure (HF) are at heightened risk of depression. Depression and HF each independently affect quality of life, regardless of functional status.
Objectives
This study aimed to evaluate the effect of escitalopram treatment, compared with placebo, on hospitalization rates and quality of life among patients with systolic HF and depression.
Methods
Following questionnaire-based screening, 90 patients with reduced left ventricular ejection fraction who met the criteria for depression treatment were enrolled and randomly assigned to receive escitalopram 20 mg daily or placebo for eight weeks (45 participants per group). After eight weeks, patients completed the quality-of-life questionnaire again.
Results
Of the ninety patients, 42 from the treatment group and 39 from the control group successfully completed the study. No significant differences in MLHFQ scores or hospitalization rates were observed between the intervention and control groups.
Conclusions
In patients with chronic HF and reduced LVEF who have depression, treatment with escitalopram did not result in a notable improvement in quality of life or a decrease in hospitalization rates compared with placebo.
Zitieren
APA
Sadeghi, R., Pourrajab, F., Mahjoob, M. P., Shams, J., & Aghajani, M. H. (2026). The Effect of Escitalopram Treatment Compared to Placebo on Improving the Quality of Life and Hospitalization Rate of Patients with Systolic Heart Failure and Depression: A Randomized Controlled Trial. International Journal of Cardiovascular Practice, 11(2). https://doi.org/10.5812/intjcardiovascpract-175695
Vancouver
Sadeghi R, Pourrajab F, Mahjoob MP, Shams J, Aghajani MH. The Effect of Escitalopram Treatment Compared to Placebo on Improving the Quality of Life and Hospitalization Rate of Patients with Systolic Heart Failure and Depression: A Randomized Controlled Trial. International Journal of Cardiovascular Practice. 2026;11(2). doi:10.5812/intjcardiovascpract-175695
BibTeX
@article{Sadeghi2026,
author = {Sadeghi, Roxana and Pourrajab, Farnaz and Mahjoob, Mohammad Parsa and Shams, Jamal and Aghajani, Mohammad Haji},
title = {The Effect of Escitalopram Treatment Compared to Placebo on Improving the Quality of Life and Hospitalization Rate of Patients with Systolic Heart Failure and Depression: A Randomized Controlled Trial},
journal = {International Journal of Cardiovascular Practice},
year = {2026},
volume = {11},
number = {2},
doi = {10.5812/intjcardiovascpract-175695}
}
EUVIMED